News Details

Chimerix, Exclusive Licensee of Cantex' Lead Product DSTAT, has Announced Initiation of a Phase 2/3 Study of DSTAT, Formerly Known as CX-01, in Acute Lung Injury for Patients with Severe COVID-19

About Chimerix, Inc.
  • NASDAQ: $CMRX
  • Notified: $1.94
  • 08:42 EDT

Price Chart